Funding For Healthcare In Latvia Is Managed By The State Compulsory Health Insurance Agency
Posted on: Wednesday, 17 January 2007, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c48711) has announced the addition of "The Pharmaceutical Market: Latvia" to their offering.
Latvia is one of the smallest countries in Europe. It joined the EU in May 2004 and NATO two months earlier. The 2006 population is estimated to be 2.3 million, with the most populous city being Riga, the capital. As with other European countries, Latvia has an ageing population, with those aged 65 and over representing 16.5% of the population in 2006, compared to 14.5% in 1999.
Funding for healthcare in Latvia is managed by the State Compulsory Health Insurance Agency, although funds are gathered largely through general taxation. Treatments guaranteed to all Latvians and foreign residents include emergency care, treatment for acute and chronic diseases, maternity care, prevention and treatment of infectious diseases (including tuberculosis and HIV/AIDS), immunisation coverage, oncology, haematology and provision of certain pharmaceuticals to eligible groups.
Around 70% of the pharmaceutical market is supplied by imports. Switzerland, Lithuania and Germany were the leading suppliers in 2004, accounting for almost 50% of imports. Imports have increased in value terms every year since 2001.
The European Regional Development Fund and the Latvian government are currently funding the National Programme in the Area of Healthcare 2004-2006, worth 11.3 million lats (US$6.1 million). The programme consists of a number of projects aimed at improving primary healthcare. One of the objectives is to improve the availability of good quality pharmaceutical care, medicines and objective information regarding medicines.
Espicom's in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Companies Mentioned:
Farmserviss
Magnum Medical
Mepha Latvia
Recipe Plus
Tamro SIA
Kalceks
Grindex
Olainfarm
For more information visit http://www.researchandmarkets.com/reports/c48711
Source: Business Wire
Related Articles
- Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
- This 2008 China Pharmaceutical Regulatory Report Includes a Brief Overview of the Pharmaceutical and Healthcare Industry in China
- Realize the Importance of Strategic Pricing & Maximize Profits in This Outcomes-Based Pharmaceutical Pricing Report
- Bio-Imaging Technologies to Present at the BMO Capital Markets 8th Annual Focus on Healthcare Conference August 6, 2008 in New York
- The Latvia Food & Drink Report Will Give You Competitive Intelligence on Latvia's Food and Drink Industry
- European Patient Safety and Parallel Pharmaceutical Trade - A Potential Public Health Disaster?
- AMDL to Open JPGreen Health and Personal Care Center
- Catholic Health System Home Care Selects McKesson's Advanced Remote Monitoring Solution to Reshape Homecare Delivery
- Dell'Oro Group Reports Optical Transport Market Grew 9 Percent in the First Quarter of 2006; Robust North American Market Offsets Weaker European and Asian Markets
- PRAECIS PHARMACEUTICALS INCORPORATED Reports Third Quarter 2004 Financial Results and Provides Update on Plenaxis Commercialization and Clinical Development Programs
User Comments (0)

RSS Feeds